We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amylin Pharmaceuticals, Eli Lilly and Alkermes have announced results from the
ongoing Phase II multidose study of a long-acting release (LAR) formulation
of Byetta (exenatide) injection in patients with Type 2 diabetes.
Allergan announced that the FDA has approved a less potent version of its Alphagan drug to reduce intraocular pressure in patients with open-angle glaucoma and ocular hypertension.
Nuvelo has announced the publication of data from a study of NU206, a secreted protein in preclinical development, showing that it acts as a specific and potent stimulator of the human epithelial cells that line the gastrointestinal tract and mouth.
BioMS Medical announced that its independent data safety monitoring board (DSMB) has reviewed data from its Phase II/III clinical trial of MBP8298 for the treatment of secondary progressive multiple sclerosis and recommended that the trial continue.
Panacos Pharmaceuticals announced the successful completion of a Phase IIa clinical study of its lead HIV drug candidate, PA-457, and provided preliminary analysis of the results.
Nuvelo announced enrollment of the first patient in a Phase II clinical trial evaluating rNAPc2 (recombinant nematode anticoagulant protein c2) as a potential replacement for heparin in patients being treated for acute coronary syndromes (ACS).
Endo Pharmaceuticals has reported the results from the Phase III clinical trial of its investigational drug oxymorphone extended-release tablets (oxymorphone ER) that was conducted under the FDA's special protocol assessment process.